This Level 1 multicenter RCT compared characterized chondrocyte implantation (CCI) with microfracture for single symptomatic grade III-IV cartilage defects of the femoral condyle. CCI uses a gene-scored, quality-selected chondrocyte population designed to form stable hyaline-like cartilage. The study asked whether CCI produces structurally superior repair tissue at 1 year while remaining clinically at least as good as microfracture.
When you counsel a patient with a symptomatic femoral condyle chondral defect, remember the core trade-off this trial exposes: cell-based repair builds better tissue, but that structural edge does not show up in symptoms within the first year.
Microfracture fills the defect with fibrocartilage by stimulating marrow across a violated subchondral plate. That tissue is less durable and can degenerate, while ACI-type repair keeps remodeling.
The authors expect any clinical divergence to emerge only at 2 to 3 years, so this paper does not justify choosing CCI for faster recovery. In the short term both do equally well by KOOS, and microfracture is one operation instead of two.
The key mechanistic teaching point for boards: conventional ACI cells dedifferentiate during expansion, and characterizing cells by a hyaline-predictive gene score is the proposed fix. Counsel CCI patients about early swelling, crepitation, and roughly 25% hypertrophy risk.
This Level 1 multicenter RCT compared characterized chondrocyte implantation (CCI) with microfracture for single symptomatic grade III-IV cartilage defects of the femoral condyle. CCI uses a gene-scored, quality-selected chondrocyte population designed to form stable hyaline-like cartilage. The study asked whether CCI produces structurally superior repair tissue at 1 year while remaining clinically at least as good as microfracture.
When you counsel a patient with a symptomatic femoral condyle chondral defect, remember the core trade-off this trial exposes: cell-based repair builds better tissue, but that structural edge does not show up in symptoms within the first year.
Microfracture fills the defect with fibrocartilage by stimulating marrow across a violated subchondral plate. That tissue is less durable and can degenerate, while ACI-type repair keeps remodeling.
The authors expect any clinical divergence to emerge only at 2 to 3 years, so this paper does not justify choosing CCI for faster recovery. In the short term both do equally well by KOOS, and microfracture is one operation instead of two.
The key mechanistic teaching point for boards: conventional ACI cells dedifferentiate during expansion, and characterizing cells by a hyaline-predictive gene score is the proposed fix. Counsel CCI patients about early swelling, crepitation, and roughly 25% hypertrophy risk.